The commercially available ExoDx Prostate Intelliscore test, which determines the expression levels of PCA3 and ERG in uEV, has, to date, only been investigated to stratify PCa patients for AS enrollment [53] but not for AS monitoring. This evidence concerns the gene ERG and posterior cortical atrophy.